Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy

Institute of Liver and Biliary Sciences, India

Overview

All patients with chronic kidney disease (stages 3, 4 and 5) and chronic dialysis patients with HCV infection attending nephrology and Hepatology OPD or getting outpatient dialysis at the dialysis unit of ILBS.

Study Type

OBSERVATIONAL

Conditions

CKD With Hepatitis C

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with moderate to severe renal dysfunction (CKD stage 3, 4, 5) and chronic dialysis patients 2. Patients consented for the study protocol by signing the informed consent. Exclusion Criteria: 1. Age less than 18 years 2. Confirmed pregnancy 3. HCV-HIV Co infection 4. HBV-HCV co infection

Locations (1)

Institute of liver and Biliary Sciences

New Delhi, National Capital Territory of Delhi, India

Outcomes

Primary Outcomes

Sustained Virologic Response 24 defined as HCV RNA <Lower Level of Qunatification 24 weeks after discontinuation of therapy.

Time frame: 1 year

Secondary Outcomes

number of adverse Events in both groups

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.